Ambroxol HCl
产品说明书
 |
同义名 : | NA-872 hydrochloride;Ambroxol hydrochloride;Mucosolvan;Ebromin;Duramucal;Ambro-Puren Ambrobeta;Ambril;Abrohexal;NA 872 |
| CAS号 : | 23828-92-4 | |
| 货号 : | A118627 | |
| 分子式 : | C13H19Br2ClN2O | |
| 纯度 : | 97% | |
| 分子量 : | 414.564 | |
| MDL号 : | MFCD00078932 | |
| 存储条件： |
Pure form Inert atmosphere,2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
H2O: 8 mg/mL(19.3 mM)，配合低频超声助溶 |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Ambroxol hydrochloride, an active metabolite of the prodrug Bromhexine, has potent expectorant effects[3]. Ambroxol hydrochloride is a glucocerebrosidase (GCase) chaperone and increases glucocerebrosidase activity. Ambroxol hydrochloride induces lung autophagy and has the potential for Parkinson disease and neuronopathic Gaucher disease research. Ambroxol hydrochloride (1, 3, 4, 5 mM for 12 consecutive days in drinking water) results in increased brain glucocerebrosidase activity in wild-type mice, transgenic mice expressing the heterozygous L444P mutation in the murine glucocerebrosidase 1 gene, and transgenic mice overexpressing human α-synuclein[4]. In addition, ambroxol hydrochloride improved motor recovery and muscle re-innervation after transient sciatic nerve injury in non-transgenic mice and promoted axonal elongation in an in vitro model of motor unit[5]. Ambroxol hydrochloride administered intravenously more than 48 hours prior to chemotherapy optimally increased the concentrations of paclitaxel and carboplatin in lung tissue without significantly increasing hematologic toxicity[6]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00144274 | Pharyngitis | Phase 3 | Completed | - | South Africa ... 展开 >> Boehringer Ingelheim Investigational Site Boksburg, South Africa, 1461 Boehringer Ingelheim Investigational Site Cape Town, South Africa, 7646 Boehringer Ingelheim Investigational Site Cape Town, South Africa, 7700 Boehringer Ingelheim Investigational Site Cape Town, South Africa, 7945 Boehringer Ingelheim Investigational Site Durban, South Africa, 4091 Boehringer Ingelheim Investigational Site Johannesburg, South Africa, 2033 Boehringer Ingelheim Investigational Site Johannesburg, South Africa, 2192 Boehringer Ingelheim Investigational Site Krugersdorp, South Africa, 1739 Boehringer Ingelheim Investigational Site Midrand, South Africa, 1685 Boehringer Ingelheim Investigational Site Pretoria, South Africa, 0038 Boehringer Ingelheim Investigational Site Pretoria, South Africa, 0157 Boehringer Ingelheim Investigational Site Sandton, South Africa, 2021 收起 << |
| NCT00148499 | Pharyngitis | Phase 3 | Completed | - | Romania ... 展开 >> Medicover Bucharest, Romania, 010224 Medicover Bucharest, Romania, 010626 Medicover Bucharest, Romania, 021106 Victor Babes Clincial Hospital Bucharest, Romania, 030303 Ukraine Regional Student Hospital Kharkov, Ukraine, 61002 Regional Clinical Hospital Kharkov, Ukraine, 61022 City Clinical Otolaryngological Hospital Kharkov, Ukraine, 61024 City Clinical Hospital No. 17 Kharkov, Ukraine, 61037 City Clinical Hospital No. 11 Kharkov, Ukraine, 61050 City Clinical Hospital No. 26 Kharkov, Ukraine, 61072 Academy of Medical Science named after O.S. Kolomyichenko Kiev, Ukraine, 03057 City Clinical Hospital No. 9 Kiev, Ukraine, 04112 City Clinical Hospital No. 11 Odessa, Ukraine, 65006 Regional Clinical Hospital Zaporozhye, Ukraine, 69600 收起 << |
| NCT03583658 | Pharyngitis | Phase 3 | Completed | - | South Africa ... 展开 >> Investigational Site Number 7100005 Johannesburg, South Africa 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.41mL 0.48mL 0.24mL |
12.06mL 2.41mL 1.21mL |
24.12mL 4.82mL 2.41mL |
| 参考文献 |
|---|